Oral Solid Dosage Forms - Cardiology Markets

Introduction

Greystone Research is pleased to announce the publication of a new life science information resource, a comprehensive overview of the markets, products and participants providing the driving force behind the OSDF segment of the drug delivery sector. The report has been designed and developed to provide pharmaceutical company decision makers, drug developers and formulators, drug device designers, and industry strategists with a detailed understanding of the expanding impact of Ora; Solid Dosage Forms on therapies, pharmaceutical strategies and healthcare treatment protocols. Provider organization business managers, healthcare administrators and investors will also benefit from this publication.

Generating Product Improvements in a Mature Market

The generic solid dosage form drug segment is a rapidly evolving and highly unpredictable environment that has been a challenge to decision makers attempting to map strategies for success in this segment. There are 600 distinct APIs for which there is at least one approved generic solid dosage form ANDA. These APIs account for over four thousand approved ANDAs. Including all approved doses, the current universe of generic solid dosage forms consists of thousands of unique tablet and capsule products. These products are marketed and supplied by more than 800 companies. Competition among the various drug and therapeutic classes is uneven, with the top ten segments accounting for a disproportionate level of activity and revenue. Understanding the underlying factors affecting business performance is key to attaining financial targets.

FDA Approved Hypertension APIs

SAMPLE VIEW

OSDF drugs indicated for Hypertension represent more than 90 % of all approved APIs in the Cardiology market segment. This group includes a number of well-known prescription medicines, including:

Other non-hypertensive drugs approved for Cardiology indications include APIs indicated for Angina, Dyslipidemia, Heart Rhythm, Myocardial Infarction, and Peripheral Blood flow.

Drug Strength and Dosing

The visualization on the below illustrates the formulation challenges for OSDF service and technology suppliers. The wide range of dosing categories and the resulting process and QA issues they represent presents opportunities as well facility and equipment issues.

SAMPLE VIEW